Full metadata record
DC Field | Value | Language |
---|---|---|
dc.creator | Nistal-Villan, E. (Estanislao) | - |
dc.creator | Buñuales, M. (María) | - |
dc.creator | Poutou, J. (Joanna) | - |
dc.creator | Gonzalez-Aparicio, M. (Manuela) | - |
dc.creator | Bravo-Perez, C. (Carlos) | - |
dc.creator | Quetglas, J.I. (José Ignacio) | - |
dc.creator | Carte, B. (Beatriz) | - |
dc.creator | González-Aseguinolaza, G. (Gloria) | - |
dc.creator | Prieto, J. (Jesús) | - |
dc.creator | Larrea, E. (Esther) | - |
dc.creator | Hernandez-Alcoceba, R. (Rubén) | - |
dc.date.accessioned | 2016-03-14T15:31:53Z | - |
dc.date.available | 2016-03-14T15:31:53Z | - |
dc.date.issued | 2015 | - |
dc.identifier.citation | Nistal-Villan E, Buñuales M, Poutou J, González-Aparicio M, Bravo-Perez C, Quetglas JI,et al. Enhanced therapeutic effect using sequential administration of antigenically distinct oncolytic viruses expressing oncostatin M in a Syrian hamster orthotopic pancreatic cancer model. Mol Cancer 2015;14(1):210 | es_ES |
dc.identifier.issn | 1476-4598 | - |
dc.identifier.uri | https://hdl.handle.net/10171/40203 | - |
dc.description.abstract | The limited efficacy of current treatments against pancreatic cancer has prompted the search of new alternatives such as virotherapy. Activation of the immune response against cancer cells is emerging as one of the main mechanisms of action of oncolytic viruses (OV). Direct oncolysis releases tumor antigens, and viral replication within the tumor microenvironment is a potent danger signal. Arming OV with immunostimulatory transgenes further enhances their therapeutic effect. However, standard virotherapy protocols do not take full advantage of OV as cancer vaccines because repeated viral administrations may polarize immune responses against strong viral antigens, and the rapid onset of neutralizing antibodies limits the efficacy of redosing. An alternative paradigm based on sequential combination of antigenically distinct OV has been recently proposed. | es_ES |
dc.description.sponsorship | This work has been funded by grants from the Spanish Department of Science (SAF2009-11324 and SAF2012-39578, to RH); Fondo Investigación Sanitaria (PI10/00149 to EL); Fundacion Fuentes Dutor; the Spanish MINECO Fellowship JCI-2011-09179 and SAF2012-39578; the ISCIII, cofounded by FEDER grant No. PI11/01534 and the European Marie-Curie IRG-2010-277172 to ENV and GGA | es_ES |
dc.language.iso | eng | es_ES |
dc.publisher | BioMed Central | es_ES |
dc.relation | info:eu-repo/grantAgreement/EC/FP7/277172 | - |
dc.rights | info:eu-repo/semantics/openAccess | es_ES |
dc.subject | Oncolytic viruses | es_ES |
dc.subject | Pancreatic cancer | es_ES |
dc.subject | OSM | es_ES |
dc.subject | Andenovirus | es_ES |
dc.subject | NDV | es_ES |
dc.subject | Materias Investigacion::Ciencias de la Salud | es_ES |
dc.title | Enhanced therapeutic effect using sequential administration of antigenically distinct oncolytic viruses expressing oncostatin M in a Syrian hamster orthotopic pancreatic cancer model | es_ES |
dc.type | info:eu-repo/semantics/article | es_ES |
dc.identifier.doi | http://dx.doi.org/ 10.1186/s12943-015-0479-x | es_ES |
Files in This Item:
Statistics and impact
Items in Dadun are protected by copyright, with all rights reserved, unless otherwise indicated.